Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Common Equity (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Common Equity for 14 consecutive years, with $14.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 53.84% to $14.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.2 million, a 53.84% decrease, with the full-year FY2025 number at $19.0 million, down 31.57% from a year prior.
  • Common Equity was $14.2 million for Q4 2025 at Aytu Biopharma, down from $23.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $137.6 million in Q2 2021 to a low of $14.2 million in Q4 2025.
  • A 5-year average of $47.9 million and a median of $34.9 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 44.79% in 2021, then crashed 67.79% in 2022.
  • Aytu Biopharma's Common Equity stood at $105.5 million in 2021, then plummeted by 56.59% to $45.8 million in 2022, then dropped by 28.3% to $32.9 million in 2023, then dropped by 6.36% to $30.8 million in 2024, then plummeted by 53.84% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Common Equity are $14.2 million (Q4 2025), $23.2 million (Q3 2025), and $19.0 million (Q2 2025).